TABCs play a positive role in tumor growth and, particularly in tumor chemoresistance through the release of the growth factor insulin-like growth factor 1 (IGF-1), mediating the appearance of heterogeneous tumor cell populations resistant to BRAF and/or MEK inhibitors [211]. The gene discussed is IGF1; the disease is neoplasm.